Steady‐state pharmacokinetics of once‐daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers

• Published in: HIV medicine Vol. 8; no. 7; pp. 457 - 464
• Main Authors: Luber, AD, Brower, R, Kim, D, Silverman, R, Peloquin, CA, Frank, I
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.10.2007
• Subjects: Adult; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - pharmacokinetics; Area Under Curve; atazanavir; Atazanavir Sulfate; Carbamates - administration & dosage; Carbamates - pharmacokinetics; Drug Therapy, Combination; Female; fosamprenavir; HIV Infections - drug therapy; Humans; Male; Oligopeptides - administration & dosage; Oligopeptides - pharmacokinetics; omeprazole; Omeprazole - administration & dosage; Omeprazole - pharmacokinetics; Organophosphates - administration & dosage; Organophosphates - pharmacokinetics; Proton Pump Inhibitors - administration & dosage; Proton Pump Inhibitors - pharmacokinetics; Pyridines - administration & dosage; Pyridines - pharmacokinetics; Sulfonamides - administration & dosage; Sulfonamides - pharmacokinetics

Objectives Use of proton pump inhibitors in HIV‐infected patients is common. The purpose of this study was to determine the steady‐state pharmacokinetics of once‐daily (qd) fosamprenavir/ritonavir (FPV/r) and atazanavir/ritonavir (ATV/r) alone and in combination with 20 mg qd omeprazole (OMP) in hea...